Spots Global Cancer Trial Database for recurrent grade 3a follicular lymphoma

Every month we try and update this database with for recurrent grade 3a follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	NCT02446457	Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade...	Laboratory Biom... Lenalidomide Pembrolizumab Rituximab	18 Years -	M.D. Anderson Cancer Center
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	NCT04205409	Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant...	Nivolumab	18 Years -	University of Washington
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.	NCT03150329	Grade 3b Follic... Recurrent B-Cel... Recurrent Class... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Prima... Recurrent Trans... Refractory B-Ce... Refractory Clas... Refractory Diff... Refractory Foll... Refractory Prim... Refractory Tran...	Laboratory Biom... Pembrolizumab Vorinostat	18 Years -	City of Hope Medical Center
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	NCT04635683	Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald...	Lenalidomide Ublituximab Umbralisib	18 Years -	Ohio State University Comprehensive Cancer Center
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	NCT02568553	Recurrent Burki... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Gray-... Recurrent Mantl... Recurrent Margi... Recurrent Media... Recurrent Non-H... Recurrent Small... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Gray... Refractory Mant... Refractory Marg... Refractory Medi... Refractory Non-... Refractory Smal...	Blinatumomab Lenalidomide	18 Years -	National Cancer Institute (NCI)
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	NCT02446457	Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade...	Laboratory Biom... Lenalidomide Pembrolizumab Rituximab	18 Years -	M.D. Anderson Cancer Center
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: